Results
1 -
10 of
27Hart S, Goh K C, Novotny-Diermayr V, Tan Y C, Madan B, Amalini C, Ong L C, Kheng B, Cheong A, Zhou J, Chng W J, Wood J M.
Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia, Blood Cancer Journal, 2011 JAK2 Inhibitors for Therapy of Myeloproliferative Neoplasms, Myeloproliferative Neoplasms Tyrosine Kinase Targeted Treatment of Chronic Myelogenous Leukemia and Other Myeloproliferative Neoplasms, Impact of Genetic Targets on Cancer Therapy Targeting Upstream Janus Kinases, STAT Inhibitors in Cancer Novel Agents Targeting Oncogenic Pathways in Lymphoma, Lymphoma Managing patients with myelofibrosis and low platelet counts, Annals of Hematology Primary myelofibrosis and its targeted therapy, Annals of Hematology Outcomes of patients with myelofibrosis treated with compassionate use pacritinib: a sponsor-independent international study, Annals of Hematology Hemmung der Janus-Kinase im Zentrum, Wiener klinisches Magazin PD-L1 als wirksames Ziel, Wiener klinisches Magazin